Evidence map›Paper›PMID 42839070›Full record

ArticleLeukemia2026

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.

Thierry Facon, Gordon Cook, Saad Z Usmani, Cyrille Hulin, Shaji Kumar, Cyrille Touzeau, Nizar J Bahlis, Supratik Basu, Hartmut Goldschmidt, Hang Quach and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Thierry FaconUniversity of Lille, CHU Lille, Service des Maladies du Sang, Lille, France.ORCID http://orcid.org/0000-0001-7705-8460
Gordon CookCancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.ORCID http://orcid.org/0000-0003-1717-0412
Saad Z UsmaniMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5484-8731
Cyrille HulinDepartment of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France.ORCID http://orcid.org/0000-0002-3749-5161
Shaji KumarDepartment of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5392-9284
Cyrille TouzeauCentre Hospitalier Universitaire, Nantes, France.ORCID http://orcid.org/0000-0003-0275-2575
Nizar J BahlisArnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.ORCID http://orcid.org/0000-0001-7353-7034
Supratik BasuRoyal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, UK.ORCID http://orcid.org/0000-0003-2206-4796
Hartmut GoldschmidtGMMG-Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-0961-0035
Hang QuachUniversity of Melbourne, St Vincent's Hospital, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-4796-3352
Mohamad MohtyHematology and Cellular Therapy Department of Saint-Antoine Hospital, Sorbonne University, Paris, France.
Christopher P VennerDepartment of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Katja WeiselDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0001-9422-6614
Noopur RajeCenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0009-0008-8300-1266
Salomon ManierUniversity of Lille, CHU de Lille, Hôpital Huriez, Service d'Hématologie, Lille, France.
Mai NgoCytel, Cambridge, MA, USA.
Marjohn ArmoonJohnson & Johnson, Horsham, PA, USA.
Kasey BolyardJohnson & Johnson, Raritan, NJ, USA.
Fredrik BorgstenJohnson & Johnson, Raritan, NJ, USA.
Robin CarsonJohnson & Johnson, Spring House, PA, USA.
Sonja ZweegmanDepartment of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. s.zweegman@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-5011-1820

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Here, we report an updated subgroup analysis by frailty status. We retrospectively performed frailty assessments using age, Charlson Comorbidity Index, and baseline Eastern Cooperative Oncology Group performance status score; patients were classified as fit, intermediate, non-frail (fit + intermediate), or frail. After a 64.5-month median follow-up, OS benefit of D-Rd versus Rd was maintained in the non-frail subgroup (median, not reached [NR] vs 69.8 months; hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.37-0.76; P = 0.0004); the OS HR point estimate favored D-Rd versus Rd in the frail subgroup (NR vs 50.4 months; HR, 0.79; 95% CI, 0.58-1.06; P = 0.1128). Improved PFS and rates of complete response or better and minimal residual disease negativity (10

Identifiers

PMID42839070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.